Incyte (NASDAQ:INCY) Rating Upgrade
Despite the company’s rating upgrade NASDAQ:INCY is at the moment trading -6.18% lower at $98.95 as of 10:07 PM New York time. Incyte’s stock is 0% over the past 200 days. It has underperformed the S&P 500 Index, which has added 6.00% over the same time period.
Out of 14 analysts covering Incyte, 15 rate it a Buy, 1 indicate a Hold while 0 suggest a Sell. The highest target is $115 and the lowest is $65 according to Thomson/First Call. The 12-month mean target is $91.36, which means downside potential of 7.67% over the current price.
Baker Bros. Advisors Lp had the largest stake with ownership of 23.50 million shares as of Q2 2015 for 20.11% of the stocks portfolio. Bb Biotech Ag is another notably bullish active investment manager who is owning 3.88 million shares of Incyte or 12.86% of their stocks portfolio. Moreover, Blue Jay Capital Management Llc have 6.6% of their stocks portfolio invested in the company for 128,169 shares. The New York-based fund Rtw Investments Llc revealed it had purchased so far a stake worth about 5.45% of the active investment manager’s stock portfolio in Incyte. The California-based fund Redmile Group Llc is also positive about the stock, possessing 191,151 shares or 4.48% of their stocks portfolio.
Incyte (NASDAQ:INCY) Profile
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea.
Incyte (NASDAQ:INCY) traded down -6.18% on 2 January, hitting $98.95. A total of 501 shares of the company’s stock traded hands. This is down from average of 1.75M shares. Incyte has a 52 week low of $98.49 and a 52 week high of $153.15. The company has a market cap of $20.88B and a P/E ratio of 0.
Get the latest Incyte (NASDAQ:INCY) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.
The post New York: Incyte (NASDAQ:INCY) Rating Outlook Improved to Outperform at RBC Capital. Lost Its Sector Perform Rating appeared first on Octafinance.